Sun Pharmaceutical Industries Limited — Others, 22-05-2025: Change in Director(s)

Sun Pharma has announced a board meeting on which it approved the financial results for the quarter and half-year ended March 31, 2025, along with a final dividend of Rs. 5.50 per share, subject to shareholder approval. Ms. Vidhi Shanghvi was appointed Whole-time Director for five years, while Mr. Sudhir Valia will retire from the Board. Consolidated Q4 sales rose 8.5% YoY to Rs. 1,281.56 Cr, driven by 13.6% India and 8.6% Global Specialty growth; US formulations declined 2.5%. FY25 saw 9% sales growth to Rs. 5,204.12 Cr, EBITDA margin at 29%, and adjusted net profit up 19% to Rs. 1198.44 Cr. Sun Pharma leads India’s pharma market with an 8.3% share and continues to expand its specialty pipeline. R&D spend was Rs. 324.84 Cr (6.2% of sales).